News

The latest findings from a post-hoc analysis of the phase 3 ENHANCE study were published in the journal Hepatology,

A recent study shows intense itching, also known as pruritus, significantly reduces the life quality of patients with primary biliary cholangitis (PBC).

Cholesterol-lowering medications known as fibrates, often used off-label to treat PBC. showed promising results in a recent study.

Patients with PBC may suffer a greater risk of developing osteoporosis, but researchers have not yet identified a definitive relationship between the two.

A recent study shows a high neutrophil-to-lymphocyte ratio may predict poor response to ursodeoxycholic acid in primary biliary cholangitis (PBC).

The FDA has accepted a New Drug Application (NDA) for elafibranor, an investigational therapeutic for the treatment of primary biliary cholangitis (PBC).

Treatment with elafibranor may improve bile flow in patients with primary biliary cholangitis (PBC), according to results of a phase 3 trial.

A study shows deep learning can be used to guide treatment, predict ALBI scores, dose UDCA and prevent use of multiple drugs in elderly adults with PBC.

Treatment of primary biliary cholangitis (PBC) with obeticholic acid may reduce negative outcomes in the disease, according to a study.

Seeking a Priority Review designation, CymaBay anticipates that the FDA will conclude its evaluation of the PBC treatment within six months.